Stock KRON KRONOS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Kronos Bio, Inc.

Equities

KRON

US50107A1043

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-11 pm EDT 		5-day change 1st Jan Change
1.15 USD +20.93% Intraday chart for Kronos Bio, Inc. +55.62% -8.00%
May. 23 Kronos Bio, Inc. to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology Annual Meeting CI
May. 21 Kronos Bio, Inc. Announces Executive Changes CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kronos Bio, Inc. to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology Annual Meeting
Kronos Bio, Inc. Announces Executive Changes
Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Kronos Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Kronos Bio, Inc. Announces to Assess KB-0742 At Planned New Dose Schedule in Ongoing Phase 1/2 Study
Kronos Bio Plans to Reduction in Force
Kronos Bio Announces Management Shakeup, 3 Top Managers to Step Down in February
Kronos Bio, Inc. Announces Executive Changes
Kronos Bio, Inc. Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
Kronos Bio Insider Bought Shares Worth $1,470,395, According to a Recent SEC Filing
Kronos Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Kronos Bio to Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 Kb-0742 Study At the Connective Tissue Oncology Society Annual Meeting
Kronos Bio, Inc. Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC
Kronos Bio Appoints Sandra Gardiner as Interim Chief Financial Officer
Kronos Bio, Inc. Appoints Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer
Kronos Bio Finance Chief Yasir Al-Wakeel Resigning
Kronos Bio Announces Resignation of Yasir Al-Wakeel as Head of Corporate Development, Effective from September 15, 2023
Kronos Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Kronos Bio, Inc. Appoints Marc Besman as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KRON Stock
  4. News Kronos Bio, Inc.
  5. Other languages